SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 1,183.14 |
| Enterprise Value ($M) | 1,203.24 |
| Book Value ($M) | 251.18 |
| Book Value / Share | 5.33 |
| Price / Book | 4.71 |
| NCAV ($M) | -7.90 |
| NCAV / Share | -0.17 |
| Price / NCAV | -149.76 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.29 |
| Return on Assets (ROA) | -0.48 |
| Return on Equity (ROE) | -1.14 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.26 |
| Current Ratio | 4.49 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 384.82 |
| Assets | 643.90 |
| Liabilities | 392.72 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 186.37 |
| Operating Income | -106.64 |
| Net Income | -160.91 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -70.94 |
| Cash from Investing | -107.20 |
| Cash from Financing | 336.60 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Eventide Asset Management, Llc | 5.78 | 30.95 | |
| 13G | Vanguard Group Inc | 5.31 | ||
| 13G | BlackRock Inc. | 5.40 | 50.94 | |
| 13D/A | New Enterprise Associates 16, L.P. | |||
| 13G | Biotechnology Value Fund L P | 9.40 | ||
| 13D/A | Frazier Life Sciences IX, L.P. | 13.40 | 41.15 | |
| 13G/A | Flynn James E | 0.00 | -100.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 93,640 | 469,774 | 19.93 | |
| 199,504 | 218,245 | 91.41 | |
| 56,836 | 205,088 | 27.71 | |
| 36,137 | 154,763 | 23.35 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| LXEO – Lexeo Therapeutics, Inc. | MACK – Merrimack Pharmaceuticals, Inc. |
| MDWD – MediWound Ltd. | MNKD – MannKind Corporation |
| MNOV – MediciNova, Inc. |
Financial data and stock pages provided by
Fintel.io